Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06126731 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 24, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site details revised at 1 of 2 sitesv4
  2. Site details revised at 1 of 2 sitesv3
  3. Primary completion date: Jun 30, 2024 to Jun 30, 2026
    • Study completion date: Jul 31, 2025 to Jun 30, 2027
    • Site details revised at 1 of 2 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
PROMIZE is an open-label, multi-centre, single-arm, Phase I/II clinical trial, evaluating the safety, tolerability and anti-tumuor efficacy of an antibiotic combination and enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
Trial Details
NCT Number NCT06126731
Lead Sponsor Institute of Cancer Research, United Kingdom
Collaborators: Prostate Cancer Foundation
Conditions
(from sponsor)		 Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Enrollment 39 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov